The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.

Hanumant Chouhan Tarik SammourMichelle L ThomasJames W Moore

Published in: Journal of surgical oncology (2018)

In this historical cohort, MSI testing is predictive of response to adjuvant chemotherapy in stage III colon cancer, but only when results are interpreted in combination with BRAF. This supports the role of routine testing for these biomarkers.

Keyphrases

metastatic colorectal cancer
early stage
wild type
clinical practice
locally advanced
squamous cell carcinoma
free survival
radiation therapy
rectal cancer